A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

1989 ◽  
Vol 28 (4) ◽  
Author(s):  
Albrecht Lindemann ◽  
Klaus H�ffken ◽  
ReinholdE. Schmidt ◽  
Volker Diehl ◽  
Otto Kloke ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Malignant Melanoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Study ◽  
Interleukin 2

A phase II study of chronic low dose of interleukin-2 (IL-2) and α-interferon (IFN-α) in Metastatic Renal Cell Carcinoma (MRCC)

2002 ◽  
Vol 1 (1) ◽  
pp. 109
Author(s):  
Michele Potenzoni ◽  
Luigi Benecchi ◽  
Nicoletta Uliano ◽  
Federico Cantoni ◽  
Matteo Dalla Chiesa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Study ◽  
Interleukin 2

A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma

2013 ◽  
Vol 36 (9) ◽  
pp. 490-495 ◽  
Author(s):  
Uday B. Dandamudi ◽  
Musie Ghebremichael ◽  
Jeffrey A. Sosman ◽  
Joseph I. Clark ◽  
David F. McDermott ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Interleukin 2 ◽  
High Dose

A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma

1997 ◽  
Vol 44 (6) ◽  
pp. 348-351 ◽  
Author(s):  
A. Piga ◽  
Paolo Giordani ◽  
Agata Quattrone ◽  
Marco Giulioni ◽  
Giorgio De Signoribus ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Study ◽  
Interleukin 2 ◽  
Advanced Renal Cell Carcinoma ◽  
Interferon Α

Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.

1992 ◽  
Vol 10 (5) ◽  
pp. 753-759 ◽  
Author(s):  
P F Geertsen ◽  
G G Hermann ◽  
H von der Maase ◽  
K Steven
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Interleukin 2 ◽  
Single Center ◽  
Recombinant Interleukin 2

PURPOSE A single-center phase II study was performed to evaluate the efficacy of recombinant interleukin-2 (rIL-2) administered by continuous infusion to patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS Thirty-one patients with RCC were entered onto the study. rIL-2 (Proleukin; Eurocetus Corp, Amsterdam, The Netherlands) was administered intravenously in a dose of 18 x 10(6) IU/m2 per 24 hours. A maximum of two induction cycles and four maintenance cycles were given. Each induction cycle consisted of two rIL-2 infusion periods of 120 hours and 108 hours duration, respectively; these were separated by a 6-day rest period. Each maintenance cycle consisted of a 120 hours rIL-2 infusion period. RESULTS Six of 30 assessable patients (20%) responded; two (7%) with a complete response (CR) and four (13%) with a partial response (PR). The response duration for patients with CR was 209 and 715+ days, and for those with PR 161, 197, 245, and 353 days. Seven patients had stable disease (SD) with a median duration of 261 days (range, 127 to 381 days). The overall median survival was 261 days (range, 13 to 905+ days). The most frequent toxicities requiring dose reductions of rIL-2 were: hypotension in 87% of patients, dyspnea in 32%, CNS toxicity in 55%, and an increase in serum creatinine levels in 48%. Septicemia occurred in 16% of patients. Toxicities usually reversed on interruption of rIL-2 infusion. One patient (3%) died as a result of the treatment from initial CNS toxicity followed by multiorgan failure. CONCLUSIONS The study confirmed the antitumor efficacy of rIL-2 administered by continuous infusion in patients with metastatic RCC. The response rate was similar to that obtained by high-dose bolus injections of rIL-2. Toxicity was substantial but manageable in a specialized oncology ward without routine use of an intensive care unit.

Sign in / Sign up

Export Citation Format

Share Document